W e thank Dr Nelson for his thoughtful comments regarding our manuscript and appreciate his emphasis on the role of biologic heterogeneity in retinal clinical trial outcomes. His perspective highlights an important challenge in retinal drug development. It draws attention to a factor that may contribute substantially to variability in treatment response, patient selection, and overall trial outcomes.
The challenges associated with biologic heterogeneity may contribute to several of the issues outlined in our review, including variable treatment responses, inconsistent efficacy signals, and difficulties in identifying patient populations most likely to benefit from a given therapeutic intervention. As retinal therapeutics become increasingly targeted, a stronger understanding of biologic heterogeneity may be increasingly important for streamlining trial design and therapeutic development.
The incorporation of biomarkers, advanced imaging, molecular profiling, and endotype-based patient stratification may provide opportunities to improve patient selection, enhance trial efficiency, and facilitate the identification of patient populations most likely to benefit from investigational therapies.
We appreciate the contribution of Dr Nelson to this discussion and agree that continued efforts to characterize biologically distinct patient populations will be important for the future of retinal clinical research. As discussed in our original article, clinical trial outcomes are influenced by a complex assortment of scientific, operational, and patient-related factors. Although the relative contribution of each factor may be difficult to quantify, improved characterization of biologic heterogeneity may help address some of these challenges while enhancing the interpretability, efficiency, and overall success of future clinical trials.
Continued discussion surrounding the numerous factors influencing clinical trial outcomes will be essential to advancing retinal drug development and improving the incorporation of promising therapies into clinical practice.
See the original article for any disclosures of the authors.
CRediT authorship contribution statement
Stay updated, free articles. Join our Telegram channel
Full access? Get Clinical Tree
